



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Te Application of:

Annie Yang et al.

Application No.: 10/716,359

Filed: November 18, 2003

For: Cell Regulatory Genes, Encoded Products, and Uses Related Thereto

Examiner: Not yet known

Art Unit: 1642

Attorney Docket No.: HMV-038.04

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail, postage prepaid, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria VA 22313-1450 on September 17, 2004.

John Barretto

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97 (b)(3)

Commissioner for Patents P.O. Box 1450 Alexandria, VA 23313-1450

Sir:

In compliance with the requirements of 37 C.F.R. 1.56 and 1.97(b)(3), submitted herewith on Form PTO-1449 is a list of publications identified in a communication from the United States Patent and Trademark Office issued in a related application. Applicants respectfully request that the Examiner consider the listed publications and indicate they were considered by making appropriate notations on the attached Form 1449.

This submission does not represent that a search has been made or that no better art exists. Nor does it constitute an admission that the cited documents are material or constitute

Atty Docket No. HMV-038.04

"prior art." If the Examiner applies the listed documents as prior art against any claim in the

application and Applicants determine that the cited documents do not constitute "prior art" under

United States law, Applicants reserve the right to present to the Office the relevant facts and law

regarding the appropriate status of such documents. Applicants further reserve the right to take

appropriate action to establish the patentability of the disclosed invention over the listed

documents, should one or more of the referenced documents be applied against the claims of the

present application.

Applicants have listed dates of publication on the attached PTO-1449 for the cited

documents based on information presently available to the undersigned. However, the listed

publication dates should not be construed that the information in the cited documents was

actually published or otherwise publicly available on the date indicated.

Under 37 C.F.R. § 1.97 (b)(3), this Information Disclosure Statement is being filed before

the mailing date of the first Office Action on the merits; therefore, no fee is believed to be due in

connection with this submission. However, the Commissioner is authorized to charge any

deficiencies or credit any overpayment to/from our Deposit Account, No. 06-1448, Reference

HMV-038.04.

Date: September 17, 2004

Customer No.: 25181

Patent Group

Foley Hoag LLP

155 Seaport Boulevard

Boston, MA 02210

617-832-1000

617-832-7000 (FAX)

Respectfully Submitted,

ypelmes

Jennifer K Holmes

Reg. No. 46,778

Attorney for Applicant

. 01 .							Sheet Pag	ge 1 of 4			
Form PTO-1449 INFORMAT	LION	N DISCLOSURIOCITA	AFION HMV-	Jumber (Optional) 038.04		ation Number 16,359					
IN AN APPLICATION (Use several sheets if necessary) Applicant Yang et al.											
(03		SEP 2 3		Group Art Unit							
				nber 18, 2003 PATENT DOCUMENT	1642	,					
EXAMINER		OCUMENT NUMBEROS	ass			OVIDOL 100	FILING DA				
INITIAL	D	OCUMENT NUMBER	DATE	NAME	AME CLASS SUBCLASS IF APPROPRIAT		CIATE				
	вт	6,518,256	02/11/256	Wang et al.							
			(-) (-) (-)					- 1			
	\vdash										
	ш		FOREI	GN PATENT DOCUME	ENTS	<u>l, </u>					
	П	OCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	Translatio				
	-	0002	55		02.00	000000000000000000000000000000000000000	YES	NO			
					- 111						
					·		,				
	\Box										
	H			-							
	\sqcup						,				
		l									
			HER DOCUMEN			r, Title, Date, Pert		:.)			
	BU	Baylin et al., "KILL 17:141-142 (1997)	ER/DR5 is a DNA	A damage-inducible p53-reg	gulated death recepto	r gene," Nature	: Genetics,				
				Na Barica A.		<u> </u>					
		Beaudry et al., "The	rapeutic targeting	of the p53 tumor suppresso	r gene," Pharmaceut	ical Biotechno	logy, 592-60)0			
	BV										
				nas of the cervix: a unique m	norphological evolut	ion with cell cy	cle correlate	es,"			
	вw	Hum Pathol., 31(6):	740-744 (2000)		-						
		Damiani et al "My	canithalial cells a	nd hasal lamina in noorly di	fferentiated in situ d	uot carcinoma	of the breast	. >>			
	BX		Damiani et al., "Myoepithelial cells and basal lamina in poorly differentiated in situ duct carcinoma of the breast," Virchows Arch, 434:27-234 (1999)								
		· · · ·									
	BY	De Laurenzi et al., "Evolution of Functions within the p53/p63/p73 Family," Ann N Y Acad Sci., 926:90-100 (2000)									
	BZ	Foschini et al., "Carcinomas of the breast showing myoepithelial cell differentiation," Virchows Arch, 432:303-310									
	BL	z (1998)									
		Friedman et al., "The p53 protein is an unusually shaped tetramer that binds directly to DNA," Proc. Natl. Acad. Sci.,									
	CA										
EXAMINER		<u> </u>		DATEC	CONSIDERED						
				1							
FYAMINER:	Initi	al if citation considered	whether or not cits	ation is in conformance with MI	PEP 8 600. Draw line	through citation	if not in				
				ith next communication to the a		tillough chation					

47.7 Sheet Page 2 of 4 Form PTO-1449 Docket Number (Optional) Application Number INFORMATION DISCLOSURE CITATION HMV-038.04 10/716,359 IN AN APPLICATION Applicant (Use several sheets if necessary) Yang et al. Group Art Unit Filing Date November 18, 2003 1642 OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages Etc.) Huibregtse et al., "A cellular protein mediates association of p53 with the E6 oncoprotein of human papillomavirus types 16 or 18," The EMBO Journal, 10(13):4129-4135 (1991) Huibregtse et al., "Cloning and Expression of the cDNA for E6-AP, a Protein that Mediates the Interaction of the Human Papillomavirus E6 Oncoprotein with p53," Molecular and Cellular Biology, 13(2):775-784 (1993) Ince et al., "p63 Coordinates Anogenital Modeling and Epithelial Cell Differentiation in the Developing Female Urogenital Tract," Am Journal of Pathol., 161(4):1111-1117 (2002) CD Lazar et al., "Transforming Growth Factor on: Mutation of Aspartic Acid 47 and Leucine 48 Results in Different CE Biological Activities," Molecular and Cellular Biology, 8(3):1247-1252 (1988) Le Bras et al., "Monoclonal antibodies raised against Xenopus p53 interact with human p73," Oncogene, 21:1304-CF 1308 (2002) Levero et al., "The p53/p63/p73 family of transcription factors: overlapping and distinct functions," J Cell Sci. CG 113:1661-1670 (2000) Lohrum et al., "Regulation and function of the p53-related proteins: same family, different rules," Trends Cell Biol., CH 10(5):197-202 (2000) Mills et al., "p63 is a p53 homologue required for limb and epidermal morphogenesis," Nature, 398:708-713 (1999) Cl Nayar et al., "Immunoreactivity of ductal cells with putative myoepithelial markers: a potential pitfall in breast carcinoma," Ann Diagn Pathol., 3:165-173 (1999) O'Connell et al., "Identification of a Basal/Reserve Cell Immunophenotype in Benign and Neoplastic Endometrium: CK A Study with the p53 Homologue p63," Gynecol Oncol., 80(1):30-36 (2001) Osada et al., "Cloning and functional analysis of human p51, which structurally and functionally resembles p53," Nat Med., 4(7):839-843 (1998) CL Quade et al., "Expression of the p53 Homologue p63 in Early Cervical Neoplasia," Gynecol Oncol, 80(1):24-29 (2001)СМ Ramnani et al., "Basal Cell-Specific Anti-Keratin Antibody 34BE12: Optimizing Its Use in Distinguishing Benign Prostate and Cancer," Mod. Pathology, 12:443-444 (1999) Sakamoto et al., "Specific sequences from the carboxyl terminus of human p53 gene product form anti-parallel tetramers in solution," Proc. Natl. Acad. Sci., 9:8974-8978 (1994) co Scheffner et al., "Interaction of the Human Papillomavirus Type 16 E6 Oncoprotein with Wild-Type and Mutant Human p53 Proteins," Journal of Virology, 66(8):5100-5105 (1992)

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

DATE CONSIDERED

EXAMINER

INFORMA	LION	N DISCLOSURE CITATION	HMV-038.04		0/716,359				
1	N A	N APPLICATION	Applicant		0,710,000				
(Us	e seve	eral sheets if necessary)	Yang et al.						
			Filing Date November 18, 2003		roup Art Unit 642				
	_	OTHER DO			uthor, Title, Date, Pertinent Pages Etc.)				
					rotein Ligase in the Ubiquitination				
	CQ				·				
	CR	Schweizer et al., "A reversibly palmitoylated resident protein (p63) of an ER-Golgi intermediate compartment is related to a circulatory shock resuscitation protein," Journal of Cell Science, 4:685-694 (1993)							
	cs	Senoo et al., "A Second p53-Related Protein, p73L, with High Homology to p73," Biochem Biophys Res Commun., 248(3):603-607 (1998)							
	СТ	Signoretti et al., "Basal Cell Specific p63 is Useful in the Differential Diagnosis of benign vs. Malignant Lesions of the Prostate," Presentation at the United States and Canadian Academy of Pathology (USCAP), March 29, 2000							
	сυ	Signoretti et al., "p63 Is a Prostate Basal Cell Marker and is Required for Prostate Development," Am Journal of Pathol., 157(6):1769-1775 (2000)							
	cv	Sternlicht et al., "The Human Myoepithelial Cell Is a Natural Tumor Suppressor," Clin Cancer Research, 3:1949-1958 (1997)							
	cw	Theis et al., "A function in apoptosis other than transactivation inherent in the NH ₂ -terminal domain of p53," International Journal of Cancer, 71:858-866 (1997)							
	сх	Totten et al., "Microscopic Differential Diagnosis of Latent Carcinoma of Prostate," Arch Pathol., 55:131-141 (1953)							
	CY	Trink et al., "A new human p53 homologue," Nat. Med. 4(7):747-748 (1998)							
	cz	Urist et al., "Loss of p63 Expression is Associated with Tumor Progression in Bladder Cancer," Am Journal of Pathol., 161(4):1199-1206 (2002)							
	DA	Varma et al., "Discriminant staining patterns of small glandular and preneoplastic lesions of the prostate using high molecular weight cytokeratin (HMCK) - A study of 301 consecutive needle biopsies," Abstract, Mod Pathol., 1997, 10:93A							
	DВ	Varma et al., "Effect of Formalin Fixation and Epitope Retrieval Techniques on Antibody 34βE12 Immunostaining of Prostatic Tissues," Mod Pathol., 12:472 (1999)							
	DC	Wang et al., "Histologic and Immunophenotypic Classification of Cervical Carcinomas by Expression of the p53 Homologue p63: A Study of 250 Cases," Hum Pathol., 32(5):479-486 (2001)							
	DD	Yang et al., "Lineage-specific expression of the P53 homologue P63 in genital tract neoplasia," Abstract, Mod Pathol., January 1999, 127A							
	DE	Yang et al., "P63: a P53 homologue that is a differentiation-specific marker in cervical squamous epithelium," Abstract, Mod Pathol., January 1999, 178A							
EXAMINER			DA	TE CONSIDERED					
			or not citation is in conformance wit is form with next communication to		line through citation if not in				

4.5 Sheet Page 4 of 4 Form PTO-1449 Docket Number (Optional) Application Number INFORMATION DISCLOSURE CITATION HMV-038.04 10/716,359 IN AN APPLICATION Applicant (Use several sheets if necessary) Yang et al. Filing Date Group Art Unit November 18, 2003 1642 OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages Etc.) Yang et al., "Rare Expression of High-Molecular-Weight Cytokeratin in Adenocarcinoma of the Prostate Gland," Am J Surg Pathol., 23(2):147-152 (1999) Zeng et al., "NBP is the p53 homolog p63," Carcinogenesis, 22(2):215-219 (2001) E TRADEMARY **EXAMINER** DATE CONSIDERED EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in

conformance and not considered. Include copy of this form with next communication to the applicant.